<DOC>
	<DOCNO>NCT00846885</DOCNO>
	<brief_summary>The objective study compare rate extent absorption sumatriptan test formulation Sumatriptan Succinate 100 mg Tablets versus reference Imitrex® 100 mg Tablets feed condition .</brief_summary>
	<brief_title>Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Inclusion Criteria Nonsmoking ( i.e . nonsmoker nontobacco user least 90 day prior prestudy medical screening ) male female within age range 1840 year . Body Mass Index ( BMI = weight/height2 ) great 19 kg/m2 less 26 kg/m2 . Normal finding physical examination , vital sign ( blood pressure 100140/6090 mmHg , heart rate 5080 beats/min ) 12lead ECG . Negative drug abuse , nicotine , alcohol , hepatitis Bsurface antigen , hepatitis C HIV , female subject , pregnancy ( serum βCG ) . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator decide clinically significant . Female subject surgically sterile least six month postmenopausal least one year , avoid pregnancy prior study , study one month end study . Exclusion Criteria Known history hypersensitivity sumatriptan ( e.g . Imitrex® , Imigran® ) and/or relate drug almotriptan , naratriptan , rizatriptan zolmitriptan Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , liver kidney disease , unless judge clinically significant Principal Investigator medical designate . Known history presence food allergy , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant illness last four week prior entry study . Presence significant physical organ abnormality . Any subject history drug abuse . Any history evidence psychiatric psychological disease ( include depression ) unless deem clinically significant Principal Investigator , medical designate . Use prescription medication within 14 day precede entry study . Use monoamine oxidase ( MAO ) inhibitor drug phenelzine tranylcypromine within 30 day precede entry study . Use counter ( OTC ) medication within seven day precede entry study ( except spermicidal/barrier contraceptive product ) . Female subject : use oral contraceptive contraceptive implant ( Norplant® ) within 30 day prior drug administration depot injection progestogen drug ( e.g . DepoProvera® ) within one year prior drug administration . Female subject : presence pregnancy lactation . Any subject blood drawn within 56 day precede study , take conduct clinical study facility BCR , within lockout period specify previous study conduct BCR . Participation clinical trial investigational drug within 30 day precede study . Any subject donate blood within 56 day precede study . Any subject participate plasma donor plasmapheresis program within seven day precede study . Significant recent history asthma ( 12 year age ) . Any subject recent ( less one year ) history alcohol abuse . Known history frequent headache migraine . Any subject parental sibling history heart attack stroke occur age 40 year . Intolerance venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>